New findings on Voxzogo’s effects on bone health and growth in children
- Voxzogo shows positive results in children with achondroplasia.
- Data presented at the Pediatric Endocrine Society's annual meeting.
- Focus on arm span and growth in longitudinal studies.
BioMarin has shared new findings regarding Voxzogo, a treatment aimed at improving bone health and growth in children with achondroplasia. Presented at the Pediatric Endocrine Society's annual meeting, the data emphasizes the treatment’s long-term effects on arm span and overall skeletal development. These insights contribute to the growing body of evidence supporting Voxzogo's role in pediatric care for this condition.
The study findings indicate that treatment with Voxzogo positively influences growth and bone health over an extended period. This data was derived from longitudinal studies involving children diagnosed with achondroplasia, showcasing the potential benefits of long-term management with this therapy. Results from the research highlight significant changes in arm span measurements, which are critical indicators in evaluating growth in affected children.
The discussion surrounding Voxzogo emphasizes its importance in addressing the challenges posed by achondroplasia, a common genetic bone disorder. Ongoing studies aim to further elucidate its impact and inform treatment protocols, providing valuable information for healthcare practitioners working with this population.
